Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Medtronic invests $90M in medtech company behind one-of-a-kind TAVR tech
Anteris Technologies is known for its biomimetic transcatheter heart valve, the DurAVR THV System. The device is the first of its kind and has gained considerable attention as the TAVR market continues to grow.
STEMI cases bring high doses of radiation to the cath lab
“We're so focused on quickly taking care of the patient ... we may be forgetting about radiation safety,” one researcher explained.
Johnson & Johnson CEO celebrates company’s cardiovascular business during Q4 earnings call
Johnson & Johnson reported $24.6 billion in sales for the fourth quarter of 2025, up 9.1% from the previous year. On an earnings call with investors, the company's CEO sang the praises of the company's cardiovascular health division.
AI agent calling cath lab patients to help them prepare for treatment
Mount Sinai Hospital in New York is now using AI-powered virtual agents to call some patients before cath lab procedures. The move was designed to help nurses focus more on patient care and reduce their risk of burnout.
Treating CLTI with atherectomy fails to improve outcomes—is it worth the cost?
Atherectomy is associated with rising healthcare costs, making it important to learn as much about the procedure's long-term value as possible.

The DurAVR TAVR system from Anteris Technologies

Medtronic invests $90M in medtech company behind one-of-a-kind TAVR tech

Anteris Technologies is known for its biomimetic transcatheter heart valve, the DurAVR THV System. The device is the first of its kind and has gained considerable attention as the TAVR market continues to grow.

Ryan Madder, MD, Program Director, Interventional Cardiology Fellowship, William Beaumont University Hospital, Corewell Health East, and Michael Abiragi, MD, cardiology fellow, Frederik Meijer Heart and Vascular Institute, Corewell Health West in Grand Rapids, explain a study showing a small number of high dose cases contribute the majority of staff dose, especially STEMI.

STEMI cases bring high doses of radiation to the cath lab

“We're so focused on quickly taking care of the patient ... we may be forgetting about radiation safety,” one researcher explained.

startup business healthcare medtech heart

Johnson & Johnson CEO celebrates company’s cardiovascular business during Q4 earnings call

Johnson & Johnson reported $24.6 billion in sales for the fourth quarter of 2025, up 9.1% from the previous year. On an earnings call with investors, the company's CEO sang the praises of the company's cardiovascular health division.

Andriy Vengrenyuk, MS, senior data analyst for interventional cardiology at the Icahn School of Medicine at Mount Sinai, explains a pilot program where artificial intelligence (AI) virtual agents call patients prior to their cath lab procedures to save nursing staff time doing administrative tasks.

AI agent calling cath lab patients to help them prepare for treatment

Mount Sinai Hospital in New York is now using AI-powered virtual agents to call some patients before cath lab procedures. The move was designed to help nurses focus more on patient care and reduce their risk of burnout.

Treating CLTI with atherectomy fails to improve outcomes—is it worth the cost?

Atherectomy is associated with rising healthcare costs, making it important to learn as much about the procedure's long-term value as possible.

Medical societies, medtech companies and clinicians weigh in as CMS considers sweeping TAVR changes

CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

heart data research doctor cardiologist AI

Post-TAVR echocardiography helps predict a patient’s long-term risk of SVD

Postprocedural gradients can tell cardiologists a lot about a patient's long-term risk of structural valve deterioration.

CGuard Prime carotid stent system was cleared by the U.S. Food and Drug Administration (FDA) in June 2025.

Pivotal trial highlights safety, effectiveness of FDA-approved carotid stent

The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.